Borenius advises the shareholders of Visionix on their sale to and investment in Revenio

We advise the shareholders of Visionix International on their sale to and investment in Revenio Group Corporation. Visionix is a global leader in intelligent diagnostic, screening, refraction, and finishing solutions for eye care professionals across optical retail, optometry and ophthalmology.

The two companies will combine and create a leading turnkey solutions provider in the global eye care market with more than EUR 250 million in sales, EUR 48 million in adjusted EBITDA and over 800 employees.

The agreed debt-free, cash-free value of the transaction (enterprise value) is EUR 290 million. The consideration payable to the sellers is EUR 250 million, of which EUR 55.7 million will be paid in the form of new shares in Revenio. The share component means that Visionix’s shareholders will remain invested in the combined group and aligned with its long-term value creation.